000056256 001__ 56256
000056256 005__ 20230421130003.0
000056256 0247_ $$2doi$$a10.1093/ijnp/pyu037
000056256 0248_ $$2sideral$$a91437
000056256 037__ $$aART-2015-91437
000056256 041__ $$aeng
000056256 100__ $$aGarcia-Bueno, B.
000056256 245__ $$aPro-/antiinflammatory dysregulation in early psychosis: Results from a 1-year follow-Up study
000056256 260__ $$c2015
000056256 5060_ $$aAccess copy available to the general public$$fUnrestricted
000056256 5203_ $$aBackground: Previous studies indicated a systemic deregulation of the pro-/antiinflammatory balance in subjects after 6 months of a first psychotic episode. This disruption was reexamined 12 months after diagnosis to identify potential risk/ protective factors and associations with symptom severity.
Methods: Eighty-five subjects were followed during 12 months and the determination of the same pro-/antiinflammatory mediators was carried out in plasma and peripheral blood mononuclear cells. Multivariate logistic regression analyses were used to identify risk/protective factors. Multiple linear regression models were performed to detect the change of each biological marker during follow-up in relation to clinical characteristics and confounding factors.
Results: This study suggests a more severe systemic pro-/antiinflammatory deregulation than in earlier pathological stages in first psychotic episode, because not only were intracellular components of the inflammatory response increased but also the majority of soluble elements. Nitrite plasma levels and cyclooxygenase-2 expression in peripheral blood mononuclear cells are reliable potential risk factors and 15d-prostaglandin-J2 plasma levels a protection biomarker. An interesting relationship exists between antipsychotic dose and the levels of prostaglandin-E2 (inverse) and 15d-prostaglandin-J2 (direct). An inverse relationship between the Global Assessment of Functioning scale and lipid peroxidation is also present.
Conclusions: Summing up, pro-/antiinflammatory mediators can be used as risk/protection biomarkers. The inverse association between oxidative/nitrosative damage and the Global Assessment of Functioning scale, and the possibility that one of the targets of antipsychotics could be the restoration of the pro-/antiinflammatory balance support the use of antiinflammatory drugs as coadjuvant to antipsychotics.
000056256 536__ $$9info:eu-repo/grantAgreement/ES/MINECO-ISCIII/CIBERSAM
000056256 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000056256 590__ $$a4.333$$b2015
000056256 591__ $$aCLINICAL NEUROLOGY$$b35 / 192 = 0.182$$c2015$$dQ1$$eT1
000056256 591__ $$aPSYCHIATRY$$b28 / 142 = 0.197$$c2015$$dQ1$$eT1
000056256 591__ $$aPHARMACOLOGY & PHARMACY$$b39 / 255 = 0.153$$c2015$$dQ1$$eT1
000056256 591__ $$aNEUROSCIENCES$$b62 / 256 = 0.242$$c2015$$dQ1$$eT1
000056256 592__ $$a1.764$$b2015
000056256 593__ $$aPharmacology$$c2015$$dQ1
000056256 593__ $$aPsychiatry and Mental Health$$c2015$$dQ1
000056256 593__ $$aPharmacology (medical)$$c2015$$dQ1
000056256 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000056256 700__ $$aBioque, M.
000056256 700__ $$aMacDowell, K.S.
000056256 700__ $$0(orcid)0000-0002-7297-6104$$aSantabarbara, J.$$uUniversidad de Zaragoza
000056256 700__ $$aMartinez-Cengotitabengoa, M.
000056256 700__ $$aMoreno, C.
000056256 700__ $$aSaiz, P.A.
000056256 700__ $$aBerrocoso, E.
000056256 700__ $$aGasso, P.
000056256 700__ $$aBarcones, M.F.
000056256 700__ $$aGonzalez-Pinto, A.
000056256 700__ $$aParellada, M.
000056256 700__ $$aBobes, J.
000056256 700__ $$aMico, J.A.
000056256 700__ $$aBernardo, M.
000056256 700__ $$aLeza, J.C.
000056256 700__ $$0(orcid)0000-0002-9098-655X$$aLobo, A.$$uUniversidad de Zaragoza
000056256 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría
000056256 7102_ $$11008$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Medic.Prevent.Salud Públ.
000056256 773__ $$g18, 2 (2015), 1-10$$pInt. j. neuropsychopharmacol.$$tINTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY$$x1461-1457
000056256 8564_ $$s780788$$uhttps://zaguan.unizar.es/record/56256/files/texto_completo.pdf$$yVersión publicada
000056256 8564_ $$s106068$$uhttps://zaguan.unizar.es/record/56256/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000056256 909CO $$ooai:zaguan.unizar.es:56256$$particulos$$pdriver
000056256 951__ $$a2023-04-21-12:38:01
000056256 980__ $$aARTICLE